1. Wei SC, Duffy CR, Allison JP. Fundamental mechanisms of immune checkpoint blockade therapy. Cancer Discov. 2018;8(9):1069–86.
2. AstraZeneca. Tremelimumab (IMJUDO®; tremelimumab-actl): US prescribing information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761270s000lbl.pdf. Accessed 14 Nov 2022.
3. US Food & Drug Administration. FDA approves tremelimumab in combination with durvalumab for unresectable hepatocellular carcinoma [media release]. 24 October 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-unresectable-hepatocellular-carcinoma.
4. AstraZeneca. Imjudo (tremelimumab) in combination with Imfinzi approved in the US for patients with unresectable liver cancer [media release]. 24 October 2022. https://www.astrazeneca.com/.
5. US Food & Drug Administration. FDA approves tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small cell lung cancer [media release]. 10 Nov 2022. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-tremelimumab-combination-durvalumab-and-platinum-based-chemotherapy-metastatic-non.